Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information 
INTRODUCTION:
Although selective serotonin reuptake inhibitors (SSRTs) are routinely prescribed for acute stress disorder and early PTSD and recommended in the VA-DoD best practice guidelines, the efficacy of SSRIs as an early intervention for PTSD in service members returning from war-zone duty has still not been determined. Consequently, this study was designed to conduct a controlled trial of fluoxetine as an early intervention for recently redeployed soldiers, as well as to develop methodologies for understanding the multiple risk factors that may predict outcome. Fluoxetine was selected as the psychophannacologic agent for this study because it is well tolerated, it has a very favorable cost-benefit advantage as a generic drug, and the fact that it is the only SSRI with at least preliminary studies demonstrating its efficacy in recent-onset, war-related PTSD. Studies focusing on targeting chronic combat-related PTSD with SSRIs have shown mixed results with some small open-label studies suggesting efficacy, while two controlled trials with Vietnam veterans were negative. In a recent study of survivors of war violence in Europe, Israel, and South Africa, fluoxetine was shown to significantly reduce PTSD symptoms. Because in all prior trials there is considerable variability of response to fluoxetine, we plan to examine several predictors of efficacy. We argue that the efficacy of SSRIs for recently redeployed soldiers at risk for chronic PTSD is moderated by multiple personal, deployment, and environmental factors. It is expected that not all subjects will respond to fluoxetine. For those that do not respond to fluoxetine alone, augmentation with either buspirone or buproprion will be offered based on their reasonable tolerability, low cost and the recent findings documenting their utility as adjunctive treatments for depression.
BODY:
The approval letter has been received from the Brooke Army Medical Center IlU3, the regional IRB for the Carl R. Darnall Army Medical Center. The IlU3 has approved the protocol with the caveat that a CRADA must be completed between TEMPVA Research Group, Inc and the Carl R. Darnall Army Medical Center. The protocol has now also been approved by the Central Texas Veterans Health Care System lRB and the Research and Development Committee. The review by Kristen R. Katopol, MS, CIM, Human Subjects Protection Scientist (AMDEX Corp.) Human Research Protection Ofice (HRPO) Office of Research Protections (ORP) U.S. Army Medical Research and Materiel Command (USAMRMC) Fort Detrick is in progress. No subjects have been enrolled and will not be enrolled until final approval is obtained fiom USAMRMC.
Two research assistants have been hired. Both have master's degrees in counseling psychology and have considerable clinical experience, as well as some research experience. They are being trained on the administration of the psychological tests associated with this project and are developing the casebooks used in data collection until final approvals are given and recruitment begins. We have been assigned 3 offices and a testing area at the Carl R. Darnall Army Medical Center Resilience and Restoration Center, Bldg. 36009.
Credentialing and privileging of Drs. Peggy Pazzaglia and Paul Hicks at the Carl R. Darnall Army Medical Center has been completed. We have received assistance fiom the VA Office of Research and Development to place the CRADA in VA format. The CIRO at Ft. Sam Houston has agreed to accept the CRADA in VA format. The CRADA is being routed for signatures.
The first continuing review from the BAMC IlU3 has been approved (see Appendix 
2.
To meet FDA and DoD requirements for maintaining records of participation in clinical investigation studies and documentation of informed bnsent, as the principal investigator, you must maintain the original signed informed consent.
3.
As the principal investigator your responsibilities are as follows:
a. If authorized by the patient, ensure that a copy of the most current IRB STAMPED "Consent Form" is filed in the patient's health recordhospital chart. b. Make a written entry in the patient's health recordhealth chart of enrollment in the study. c. A change in the research plan must be reported to the DCI for submission to appropriate committees for approval prior to implementation. d. If transferred or released fiom active duty, submit to the DCI the name of the individual who will continue the study. e. If the study is terminated, submit a report to the DCI stating the study is terminated and the reason for termination. f. If any serious adverse reactions occur during the study which were not expected, they must be reported to the Chief, DCI, within 24 hours.
4. An annual research progress report, to include a copy of the most current IRB STAMPED 
1.
The Clinical Investigation Regulatory Office (CIRO) has completed review of the above-referenced externally funded protocol and has determined that subject study complies with applicable human use protection regulations and may commence at Carl R. Damall Army Medical Center.
2.
A Cooperative Research and Development Agreement (CRADA) with TEMPVA Research Group, Inc. in support of the study is planned but has not yet been received by CIRO. Please note that extramural resources may not be accepted/utilized until an approved CRADA is in place.
3.
Point of contact is Ms. Christina Jones at 221-9322. 2. The approval period is from March 24,2008 , to March 23,2009 . Approval is given to the study for no more than 300 human subjects at the Carl R. Damell Army Medical Center as outlined in the study packet.
3. After receipt of the final approval letter fmm the research office, participants may be entered into this study with the lrnpliclt understandlng that all assurances given to the Subcommittee on Human Studies regarding the execution of this study are carried out. Failure to do so will result in revocation of this authorization.
4. You are reminded that informed consent must be obtained by the principal investigator andlor research team members who have been approved by the IRB to obtain infonned consent from subjects prior to initiation of any study procedures. The informed consent must be signed, witnessed, and copies of the consent form (VA Form 10-1 086) must be given to the subject and placed in the patienrs medical record, and in a separate study file maintained in your office or laboratory. These files must be maintained for a minimum of five years following the completion of the research and will doubtless be subjected to review by this Subcommittee and by other federal agencies. In addition, any protocols involving human subjects in radiation, radioisotopes, or nuclear medicine will be retained indefinitely.
5. Any unanticipated problems or serious adverse events of this study must be reported in wr i t i ng by the investigator to this Subcommittee within 24 hours of the occurrence, whether or not these are attributed to the research project itself or to unrelated factors. In addition, adverse reactions to drugs must be reported to the Commtttee of Pharmacy and Therapeutics. If there is any question please contact the Research Department.
6. Any rnodificatlons to the study protocol or to the consent form must be reviewed by the IRB. Completion or cessation of this study should be reported to this Subcommittee as soon as possible. If modifications of any kind are put into place without IRB approval, this is a violation and non-compliance with federal and VHA regulations and policies.
7. Your study will be subjected to further continuing review on March 23, 2009. Request the continuing review submission forms be submitted to this office on January 14,2009, for review by the IRB. If the protocol or consent form is modified in any way or discontinued for any reason before the next continuing review, please notify the Subcommittee.
8. Investigators are reminded that they are personally responsible for the careful, thoughtful execution of studies involving human subjects. Conscious disregard of subjects' rights as outlined in the consent form or failure to comply with all safeguards listed in the protocol will be met with severe sanctions; Confidentiality of human subject identitylpersonal data is mandatory.
9. The Subcommittee wishes you success with this investigation. , which permits directors of Federal laboratories to enter into cooperative research and development agreements and intellectual property licenses for intellectual property owned by or assigned to the United States Government. This is not a procurement contract, grant, or cooperative agreement as those terms are used in 31 U.S.C. SS6303, 6304, and 6305.
1.2. Entire Agreement. This CRADA includes the attached SOW (Appendix) and together they constitute a single, entire document hereinafter referred to as the "Agreement."
1.3. Purpose. The purpose of this Agreement is share resources and information towards the successful completion of the RDTE project (the llStudyll). The medical objective of the Study is described in the SOW.
1.4. Statement of Work. The RDTE project, which is described in the SOW, will be conducted under a clinical research protocol which has been reviewed by the appropriate Institutional Review Board in accordance with Army Regulation 40-38, Clinical Investigation. The SOW incorporates all of the terms and provisions of these Articles by reference. In cases of apparent conflict between the terms and provisions of the SOW and these Articles, the terms and provisions of the Articles shall control.
1.5. Consideration. The Federal Parties and the Collaborating Party agree that they are entering into this Agreement for the mutual benefit of each Party. The Federal Parties and the Collaborating Party will cooperate in support of the clinical investigation protocol specified in the SOW. The RDTE project entered into under this Agreement will benefit the Federal Parties by providing valuable research experience for the Principal Investigator and medical residents involved and by providing valuable access to new drugs and medical devices for the medical treatment of Army patients. In addition, patients involved in the RDTE project may benefit directly from the medical treatment received and all medical patients will potentially benefit from the knowledge gained as a result of the RDTE project. The Collaborating Party will also benefit from the medical knowledge gained, through the evaluation of the clinical characteristics of emerging health technologies that will be applied for the public good. 2.10. "Government purpose" means any activity in which the Government is a Party, including cooperative agreements with international or multinational defense organizations, or sales or transfers by the Government to foreign governments or international organizations, and competitive procurements. Government purpose does not include for commercial purposes.
2.11. wInvention" means any invention or discovery which is or may be patentable or otherwise protected under Title 35 of the United States Code or any novel variety of plant which is or may be protected under the Plant Variety Protection Act (7 U.S.C. SS2321 et seq.).
2.12. "Made" when used in conjunction with any invention means the conception or first actual reduction to practice of such invention.
2.13. "Party" or "Parties" refers to the Federal Laboratory, the Intermediary, or the Collaborating Party or all (in singular or plural usage as indicated by the context).
2.14. "Principal Investiqator" means an individual who actually conducts a clinical investigation (i.e. under whose immediate direction a drug is administered or dispensed to a subject). In the event an investigation is conducted by a team of individuals, the Principal Investigator is the responsible leader of the team. "Subinvestigator" includes any other individual member of that team (21 C.F.R. S312.3).
2.15. "Proprietary information" means information which embodies trade secrets or which is confidential technical, business, or financial information provided that such information: a. is not generally known, or is not available from other sources without obligations concerning its confidentiality; b. has not been made available by the owners to others without obligation concerning its confidentiality; c. is not described in an issued patent or a published copyrighted work or is not otherwise available to the public without obligation concerning its confidentiality; 
Article 3 Cooperative Research
3.1. Review of Work. Periodic conferences may be held between the Parties for the purpose of reviewing the progress of the cooperative effort. It is understood that the nature of this cooperative effort is such that completion within the period of performance specified or within the resources allotted cannot be guaranteed. Accordingly, it is agreed that all cooperative research and development activities performed by either Party are to be performed on a best efforts basis.
3.2. Changes. If at any time the Principal Investigator, a Collaborating Party, or the Federal Parties determines that the research data dictates a substantial change in the direction of the work, he or she shall promptly notify the Parties, and the Parties shall make a good faith effort to agree to any necessary changes to the SOW consistent with the basic scope of research.
3.3. Assignment of Personnel. If the SOW contemplates the assignment of one Party's personnel to the other Party's facilities, then the employees shall remain employees-of the assigning Party and will not be considered as employees of the other Party for any purpose, including but not limited to any requirements to provide workersf compensation, payment of salary or other benefits, or withholding of taxes. Assigned personnel will observe the other Party's security, safety, health, and environmental facility regulations. Assigned personnel can be denied access or removed by the other Party from its facilities at its discretion. Collaborating Party personnel assigned to Federal Parties will work under the direction of the Principal Investigator only. That direction will be limited to matters within the scope of the actual research and will not extend to any matters that are normally encompassed by the employer-employee relationship. For example, the Collaborating Party is responsible for determining the working hours of its assigned personnel.
Article 4 Reports
4.1. Progress Reports. As provided in the SOW, the Parties will prepare and exchange written reports, in a timely manner, on the progress of their work, results obtained, problems encountered, and recommendations for further research and development. To the extent reasonable, further detail concerning the contents of the reports shall be provided upon request, if necessary for the other Party to fully understand the results achieved. At a minimum, the Principal Investigator will submit annual progress reports to the Parties.
4.2. Final Report. As provided in the SOW, the Parties will prepare and exchange a final report at the completion of the cooperative effort performed under this Agreement, on the progress of their work, results obtained, problems encountered, and recommendations for further research and development. To the extent reasonable, further detail concerning the contents of the report(s) shall be provided upon request if necessary for the other Party to fully understand the results achieved.
Adverse Drug Experiences, Annual Reports, Other
Investiqational New Drug Data. The Federal Parties will provide the Collaborating Party with copies of all adverse drug experience reports. The Federal Parties shall establish and maintain records and make reports to the FDA for the following Adverse Drug Experiences: (1) all serious, unexpected adverse drug experiences, (2) any significant increase in the frequency of serious unexpected adverse drug experiences, and (3) any significant increase in the frequency of therapeutic failure.
Article 5 Transfer of Funds
5.1. Payment Schedule. The payment schedule, described in the SOW, is subject to modification by mutual consent of all Parties in the event unforeseen circumstances arise which delay initiation of this project, including delays due to insufficient volunteer enrollment, actions from responsible review or regulatory authorities, lack of equipment, malfunctions, or insufficient support personnel. In the event of cancellation or termination of a research project, the Collaborating Party shall not be responsible for payments beyond such cancellation or termination date except for payments which have accrued prior to said date and as yet remain unpaid. The U.S. Government shall not reimburse the Collaborating Party for its expenditures prior to cancellation or termination of the research project. 5.5. Accounting Records. BAMC and the Collaborating Party shall each maintain separate and distinct current accounts, records, and other evidence supporting all its expenditures under this Agreement. The accounts and records of BAMC which are relevant to the conduct of this project shall be available for reasonable inspection and copying by the Collaborating Party or its authorized representative.
Article 6
Personal and Real Property 6.1. Personal Property. Any tangible personal property provided by a Party during the performance of this Agreement shall remain the personal property of the Party providing it, unless otherwise agreed in the SOW. Property provided by a Party to another Party may only be used for the performance of the cooperative effort under this Agreement, unless otherwise agreed in the SOW. Government property may be repaired or modified by the Collaborating Party at its expense only after obtaining the written approval of the Federal Parties. Any repair or modification of the property shall not affect the title of the Government. The Federal Parties makes no warranty, express or implied, with respect to property contributed or loaned by it. Upon completion of the cooperative effort performed under this Agreement, each Party shall immediately account for the property in its possession and return, at its expense, all property belonging to the other Party in the condition in which it was received, normal wear and tear excepted. Any disposal of property shall be in accordance with applicable Federal, State, and local environmental laws and regulations.
6.2. Real Property. Any real property made available for use by a Party to another Party for the performance of this Agreement shall remain the property of the Party providing it. Any use of such property shall be in accordance with all applicable Federal, State, and local laws and regulations to include environmental laws and regulations.
Article 7 P a t e n t s
Each Party shall promptly disclose in writing to the other Party Subject Inventions made by its employees or subcontractors in sufficient detail to enable someone with skill in the art to make and use the inventions. Parties shall coordinate patent filing, prosecution, and patent maintenance payments with their respective patent counsels. Article 9 Prepublication Review 9.1. Publication. The Parties anticipate that their employees may wish to publish technical developments and/or research findings made under this Agreement. Each Party shall submit to the other Party prior to publication or other public disclosure, any proposed publication or disclosure pertaining to work under this Agreement. The other Party shall provide a written response within 30 days either objecting or not objecting to the proposed publication or public disclosure. The proposed publication or public disclosure shall not be deemed objectionable unless the proposed publication contains proprietary information, protected information, or material that would create potential statutory bars to the filing of U.S. or corresponding foreign patent applications, or for any other reasonable basis.
Article 8 P r o p r i e t a r y and P r o t e c t e d Information
9.2. Protection of Proprietary Riqhts. If requested in writing by either Party, the Collaborating Party, the Principal Investigator, and/or the Federal Parties shall withhold such submission for publication an additional 60 days to allow for filing a patent application or taking such measures as the requester deems appropriate to establish and preserve its proprietary rights in the information in the manuscript or disclosure.
Article 10 Export Control 10.1. Compliance. The Parties understand that information and technology resulting from the performance of this Agreement may be subject to export control laws and regulations, and each Party is responsible for its own compliance with such laws and regulations. Nothing in this Agreement waives any such statutory or regulatory requirement. Article 12 Force Majeure 12.1. Force Majeure Events. Neither Party shall be liable for any unforeseen event beyond its reasonable control not caused by the fault or negligence of such Party, which causes such Party to be unable to perform its obligations under this Agreement and which it has been unable to overcome by the exercise of due diligence. Such unforeseen events include, but are not limited to, fire, storm, flood, earthquake or other natural catastrophes, accidents, acts of civil disturbance or disobedience, war, rebellion, insurrection, labor strikes or disputes, compliance with any laws, requirements, rules, regulations, or orders of any governmental authority or instrumentality thereof, sabotage, invasion, quarantine, and embargoes.
12.2. Best Efforts. The excused Party shall use its best efforts to resume performance as quickly as possible and shall suspend performance for only such period as is reasonably necessary as a result of the force majeure event.
Article 13 Severability 13.1. Contrary to Law. Any provision of this Agreement, to include the SOW, that is prohibited by applicable law is void, but the remaining provisions shall survive. 14.2. Unilateral Action. Either Party may unilaterally terminate this Agreement at any time by giving the other Party written notice, not less than 30 days prior to the desired termination date.
14.3. Termination Costs. Unless otherwise specifically provided in this Agreement, each Party shall be responsible for all of the costs for which it bears responsibility under this Agreement which have been incurred through the effective date of termination. Each Party shall be solely responsible for any costs it incurs after the effective date of termination.
14.4. Continuing Obligations. In the event of termination, the Parties shall specify the disposition of all property, patents, and other results of work accomplished or in progress under this Agreement, when such disposition is not otherwise specified in this Agreement. All obligations under this Agreement to safeguard proprietary and other protected information and relating to rights in intellectual property or technical data shall survive any termination of this Agreement. The termination of this Agreement shall not affect the rights and obligations of the Parties accrued prior to the effective date of termination. 
Article 16 Modifications
16.1. Modifications. If either Party desires to modify this Agreement, the Parties, upon reasonable notice of the proposed modification by the Party desiring the change, shall confer in good faith to determine the desirability of such modification. Any resulting modification shall not be effective until a written amendment is signed by the duly authorized representatives of the Parties. Any material modification of this Agreement is subject to the authority of the Assistant Secretary of the Army (Research, Development, and Acquisition) as provided in paragraph 1.7 of this Agreement to disapprove or require modification within 30 days of the date it is presented to the Assistant Secretary.
Article 17 Interpretation
17.1. Entire Agreement. This Agreement includes Articles 1 -25 and the SOW (Appendix). Together, they constitute the entire agreement between the Parties with respect to the subject matter hereof and all prior representations or agreements relating hereto have been merged into the documents and are superseded in totality by this Agreement.
17.2. Precedence. In the event of a conflict between the terms and provisions of the SOW and the terms and provisions in the Articles, the terms and provisions in the Articles shall control.
Article 18 Notices
18.1. Notices. All notices, pertaining to or required by this Agreement, shall be in writing and shall be delivered by hand or sent by certified mail, return receipt requested, express mail, or private delivery service addressed as specified below. Any Party may change such address by written notice given to the other Party in the manner set forth.
Temple, TX 7 6 5 0 4 20.2 Waiver. None of the provisions of this Agreement shall be considered waived by any Party unless such waiver is given in writing to the other Party. The failure of a Party to insist upon strict performance of any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law, shall not be deemed a waiver of any right of any Party hereto. 23.2. Use of Name. The Collaborating Party may use, refer to, and disseminate reprints of scientific, medical, and other published articles which disclose the name of the Federal Parties consistent with U.S. copyright laws, provided such use does not constitute, or imply, an endorsement of any commercial product or service by the U.S. Government. The Collaborating Party shall take every step possible to ensure that references to the articles are accurate, and shall explicitly state that any such reference does not claim, infer, or imply an endorsement or recommendation of the product or service by the U.S. Government. E.ll. Other: IRB fee of $1,000.00 and CRADA administrative processing fee of $500.00 for CRADAs less than $10,000.00, or 5% of the value of any CRADA more than $10,000.00, excluding donated pharmaceuticals.
Article 21 Nonassignment
E.12. The above are hereinafter referred to as "Resources." Information relating to them, including data generated under this Agreement, is hereinafter referred to as "Information." Brooke Army Medical Center agrees that the Resources and Information will be used for research and clinical purposes only as provided in this Agreement. The Resources shall not be sold, offered for sale, used for commercial purposes, or furnished to any other Party without advance written approval from the Collaborating Party.
E.13.
Financial Obliqation. The continued performance of research by The Carl R. Darnall Army Medical Center under this Agreement is conditioned on the payment of funds to Carl R. Darnall Army Medical Center by the Collaborating Party as specified below. The Carl R. Darnall Army Medical Center will use the accounting procedures as required by applicable Army and Defense Finance and Accounting Service regulations for the handling of funds during the performance of the research. The Carl R. Darnall Army Medical Center shall not be obligated to perform any of the research specified herein or to take any other action required by this Agreement if the agreed-to funds are not transferred as required. The expiration/termination of this Agreement does not extinguish the obligation to pay any funds which have been earned by, -or are due and owed at, the date of expiration/termination.
E.14.
Payment Schedule. IRB Fees will be paid by the Collaborator to BAMC when approval is granted for this project. E.17. Accounting Records. When funds are provided to BAMC, it shall maintain distinct accounts, records, and other evidence supporting expenditures under this Agreement. BAMC shall provide the Collaborating Party an annual report accounting for the use of funds and a final fiscal report within four months after completing this Agreement or ending its research activities under this Agreement, if requested by the Collaborating Party. The financial accounts and records pertaining to this Agreement shall be available for reasonable inspection and copying by the Collaborating Party or its authorized representative(s).
E.18. The Payment Schedule is subject to modification by mutual consent of all Parties in the event unforeseen circumstances delay initiation of this project, including delays due to: insufficient volunteer enrollment, actions from responsible review or regulatory authorities, lack of equipment or malfunctions, or insufficient support personnel.
